Initiation of pharmacological therapy in Parkinson's disease: when, why, and how
Debate is ongoing regarding when, why, and how to initiate pharmacotherapy for
Parkinson's disease. Early initiation of dopaminergic therapies does not convey disease …
Parkinson's disease. Early initiation of dopaminergic therapies does not convey disease …
Non-motor symptoms of Parkinson's disease: diagnosis and management
The clinical diagnosis of Parkinson's disease rests on the identification of the characteristics
related to dopamine deficiency that are a consequence of degeneration of the substantia …
related to dopamine deficiency that are a consequence of degeneration of the substantia …
The impact of non‐motor symptoms on health‐related quality of life of patients with Parkinson's disease
Background: Non‐motor symptoms are detrimental to health‐related quality of life (HRQoL)
of Parkinson's disease patients. In this study, the Non‐Motor Symptoms Scale (NMSS) was …
of Parkinson's disease patients. In this study, the Non‐Motor Symptoms Scale (NMSS) was …
Health‐related quality of life in early Parkinson's disease: The impact of nonmotor symptoms
Nonmotor symptoms (NMS) are common in patients with established Parkinson's disease
(PD) and have a major impact upon quality of life. We investigated the significance of NMS …
(PD) and have a major impact upon quality of life. We investigated the significance of NMS …
[PDF][PDF] A review of Parkinson's disease
CA Davie - British medical bulletin, 2008 - Citeseer
Parkinson's disease (PD) is a common neurodegenerative disorder—a synucleinopathy—
with a prevalence of 160/100 000 in Western Europe rising to 4% of the population over 80 …
with a prevalence of 160/100 000 in Western Europe rising to 4% of the population over 80 …
Parkinson's disease: the non-motor issues
Non-motor symptoms (NMS) of Parkinson's disease remain the most under-appreciated and
under-researched when taken as a whole. Data is emerging that it is the “totaL” burden of …
under-researched when taken as a whole. Data is emerging that it is the “totaL” burden of …
Advances in Parkinson's disease: 200 years later
When James Parkinson described the classical symptoms of the disease he could hardly
foresee the evolution of our understanding over the next two hundred years. Nowadays …
foresee the evolution of our understanding over the next two hundred years. Nowadays …
Prevalence of nonmotor symptoms in Parkinson's disease in an international setting; study using nonmotor symptoms questionnaire in 545 patients
Abstract 2006, there was, no single instrument (questionnaire or scale) for attempting a
comprehensive assessment of the wide range of nonmotor symptoms (NMS) of Parkinson's …
comprehensive assessment of the wide range of nonmotor symptoms (NMS) of Parkinson's …
Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye …
A Iranzo, F Lomeña, H Stockner, F Valldeoriola… - The Lancet …, 2010 - thelancet.com
Background Patients with idiopathic rapid-eye-movement sleep behaviour disorder (IRBD)
may develop neurodegenerative conditions associated with substantia nigra dysfunction …
may develop neurodegenerative conditions associated with substantia nigra dysfunction …
Progression of Parkinson's disease in the clinical phase: potential markers
Neuromodulatory or even neuroprotective therapy could soon be available for Parkinson's
disease (PD), raising the question of how we should define and measure disease …
disease (PD), raising the question of how we should define and measure disease …